PIOMBINO DESE, Italy / Mar 11, 2025 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Healthcare Forum taking place from Tuesday, March 18 to Wednesday, March 19, 2025. The Company will present on... Read More

Introduces 2025 Guidance PIOMBINO DESE, Italy / Mar 06, 2025 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and fiscal year 2024. Fourth Quarter and Full-Year 2024 Highlights (comparisons to prior-year... Read More

PIOMBINO DESE, Italy / Feb 24, 2025 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2024 on Thursday, March 6, 2025, at 6:30 a.m.(ET). Conference call and webcast: The Company... Read More

PIOMBINO DESE, Italy / Nov 11, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences. The Company will participate in a fireside chat at the UBS Global Healthcare Conference in Rancho Palos Verdes,... Read More

PIOMBINO DESE, Italy / Nov 05, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue for the third quarter of 2024 increased 2% to €277.9 million, compared with... Read More

PIOMBINO DESE, Italy / Oct 22, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a... Read More

The platform provides a versatile pre-filled and pre-loaded on-body solution, suitable for highly viscous biological drugs PIOMBINO DESE, Italy / Oct 01, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life... Read More

Market advances adoption of ready-to-use containers Improved operational efficiency in pharmaceutical manufacturing processes Increased patient safety with high-quality sterile primary packaging PIOMBINO DESE, Italy / Sep 26, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug... Read More

PIOMBINO DESE, Italy / Aug 29, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences. The Company will present at the Morgan Stanley Healthcare Conference in New York on Friday, September... Read More

PIOMBINO DESE, Italy / Aug 06, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue for the second quarter of 2024 increased 2% to €259.6 million, compared... Read More

PIOMBINO DESE, Italy / Jul 25, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the second quarter of 2024 on Tuesday, August 6, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a... Read More

Cisterna’s site is the first to implement premium solutions outside the Group’s headquarters in Piombino Dese to meet the growing demand for biopharmaceuticals, such as GLP-1s in Europe. PIOMBINO DESE, Italy / May 30, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment,... Read More

PIOMBINO DESE, Italy / May 28, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that its Board of Directors has appointed Franco Stevanato, a... Read More

All Resolutions Proposed to Shareholders Passed PIOMBINO DESE, Italy / May 24, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders (“AGM”) held virtually on... Read More

PIOMBINO DESE, Italy / May 23, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences. The Company will present at the William Blair Growth Stock Conference in Chicago on Tuesday, June 4,... Read More

PIOMBINO DESE, Italy / May 09, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2024. First Quarter 2024 Highlights Revenue for the first quarter of 2024 decreased 1% to €236.0 million compared with... Read More

PIOMBINO DESE, Italy / May 01, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Bank of America Securities Healthcare Conference taking place from Tuesday, May 14, 2024 to Thursday, May 16, 2024. The Company will... Read More

PIOMBINO DESE, Italy / Apr 25, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a... Read More

Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. PIOMBINO DESE, Italy / Apr 04, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical,... Read More

PIOMBINO DESE, Italy / Mar 26, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the closing of its previously announced upsized underwritten public offering of an aggregate of 14,605,000 of its ordinary shares,... Read More

PIOMBINO DESE, Italy / Mar 21, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering... Read More

PIOMBINO DESE, Italy / Mar 20, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares. Stevanato Group is offering... Read More

PIOMBINO DESE, Italy / Mar 11, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum taking place from Tuesday, March 19, 2024 to Wednesday, March... Read More

Establishes 2024 Guidance PIOMBINO DESE, Italy / Mar 07, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2023. Fourth Quarter and FY 2023 Highlights (compared with the same period last... Read More

PIOMBINO DESE, Italy / Feb 22, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and year end of 2023 on Thursday, March 7, 2024, at 6:30 a.m. (ET). Conference call and webcast: The... Read More

New developments in the biopharmaceutical field fuel a need for highly scalable and flexible solutions PIOMBINO DESE, Italy / Jan 24, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences... Read More

PIOMBINO DESE, Italy / Jan 03, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the 42 nd Annual J.P. Morgan Healthcare Conference taking place from January 8, 2024 to January 11, 2024 in San Francisco, California. The... Read More

Stevanato Group recognized for excellence and leadership in implementing equipment and technology to respond to pharma companies’ needs PIOMBINO DESE, Italy / Nov 16, 2023 / Business Wire / Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology,... Read More

PIOMBINO DESE, Italy / Nov 09, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Jefferies London Healthcare Conference taking place from November 14, 2023 to November 16, 2023. The Company will present on... Read More

Reiterates Full Year 2023 Guidance PIOMBINO DESE, Italy / Oct 31, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2023. Third Quarter 2023 Highlights (compared with the same period last year) Third... Read More

PIOMBINO DESE, Italy / Oct 17, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2023 on Tuesday, October 31, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host... Read More

PIOMBINO DESE, Italy / Oct 05, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries announced today that the resolution proposed to shareholders at the Extraordinary General Meeting of Shareholders (“EGM”) held virtually on October 4, 2023 was passed. Details of the... Read More

PIOMBINO DESE, Italy / Sep 19, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, will livestream its inaugural Capital Markets Day on September 27, 2023 from 11:00 a.m. ET to approximately 2:30 p.m. ET. The livestream will be available at... Read More

Reiterates Full Year 2023 Revenue and Adjusted Diluted Earnings per Share Guidance; Increases Adjusted EBITDA Guidance PIOMBINO DESE, Italy / Jul 28, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of... Read More

PIOMBINO DESE, Italy / Jul 14, 2023 / Business Wire / Stevanato Group S.p.A . (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2023 on Friday, July 28, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a... Read More

The Company offers the platform as a readily customizable pre-filled and pre-loaded on-body solution for drug delivery. Device development is making significant progress, with samples expected to be available in 2023 PIOMBINO DESE, Italy / Jun 12, 2023 / Business Wire / Stevanato Group S.p.A . (NYSE: STVN), a leading global... Read More

PIOMBINO DESE, Italy / Jun 07, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has changed the previously announced ex-dividend date of June 5, 2023 for its cash dividend of EUR 0.054 per share, payable on July 17, 2023, to comply with... Read More

PIOMBINO DESE, Italy / May 24, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences. On June 6, 2023, management will present at the 43 rd Annual William Blair Growth Stock Conference in... Read More

Reiterates Full Year 2023 Guidance PIOMBINO DESE, Italy / May 04, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2023, and maintained its fiscal 2023 guidance. First Quarter 2023 Highlights... Read More

PIOMBINO DESE, Italy / May 02, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the upcoming BofA Securities Healthcare Conference at the Encore hotel in Las Vegas that will take place from May 9, 2023 to May 11, 2023.... Read More

PIOMBINO DESE, Italy / Apr 17, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2023 on Thursday, May 4, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a... Read More

PIOMBINO DESE, Italy / Mar 21, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today its collaboration with Thermo Fisher Scientific , the world leader in serving science, to bring to the market a fully integrated on-body delivery system platform for subcutaneous... Read More

PIOMBINO DESE, Italy / Mar 16, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with leading Contract Development and Manufacturing Organisation (CDMO), Recipharm . Under the agreement, Stevanato Group will lend its 70+ years of... Read More

PIOMBINO DESE, Italy / Mar 08, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced two separate agreements with BNL BNP Paribas and Cassa Depositi e Prestiti Group (CDP) to obtain ESG-linked funds to support its ongoing global expansion. BNL BNP Paribas is... Read More

PIOMBINO DESE, Italy / Mar 02, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2022, and established fiscal 2023 guidance. Fourth Quarter and Full Year 2022 Highlights (compared with the... Read More

PIOMBINO DESE, Italy / Feb 16, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2022 on Thursday, March 2, 2023, at 6:30 a.m. (ET). Conference call and webcast: The... Read More

Leading drug containment provider to release a unique offering including both COP and COC pre-fillable syringes (PFS), adding to its existing glass PFS portfolio, providing customers with the broadest choice for PFS PIOMBINO DESE, Italy / Jan 25, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global... Read More